IDBS Polar

Biopharma development data management

In a recent survey of biopharma development teams, participants reported **spending an average of 1 day each week, or**

20%

of their time on data administration: searching, managing, analyzing and reporting.

This is because...

50%
were using legacy applications such as Electronic Lab Notebooks (ELNs) to record process development work

50%
were using paper, Excel, and standalone software solutions which can't be searched or leveraged effectively.

And when it comes to compiling data for regulatory submissions, this results in bottlenecks:

Spending less time on data administration improves the entire development lifecycle, enabling more experimentation, better process insight and understanding, and quicker preparation of key documents, **including 50% reduction in time to prepare BLA Chapter 3**[1].

Scientists were asked where time savings would have the biggest impact



Quality, compliance, and process understanding are all under scrutiny of regulatory bodies and where digital transformation has the most positive impact on process development and scale-up.

41%
Earlier process insights to determine product quality

26%
Accurate and more rapid preparation of tech transfer documentation

15%
faster report generation

18%
Regulatory compliance with less overhead

[1] Danaher Market Research (2020)
[2] Aspen Survey (November 2020)

To learn more, visit idbs.com/polar

IDBS
contact@idbs.com
www.idbs.com/polar

BOOK A DEMO

UK (HQ) USA JAPAN GERMANY FRANCE INDIA